Action Potential Venture Capital
Dedicated to bringing bioelectronic medicines to patients.
Please follow this link to view a brief video introduction to APVC.
What is Bioelectronic Medicine
Bioelectronic medicine is an emerging therapeutic field which leverages advances in hardware, computing and material science to regulate neural or cellular activity, and more effectively treat a range of chronic diseases.
One important therapeutic target for bioelectronic medicines is the nervous system which carries electrical impulses – or action potentials – that control virtually every organ or function in our bodies. The nervous system can be modulated to treat diseases through the targeted delivery of various forms of energy including electrical, electromagnetic, and acoustic energy.
APVC is a leading medical technology venture capital firm founded by GlaxoSmithKline in 2013. We invest around the world and take a hands-on role on the boards of start-ups advancing bioelectronic medicines and their enabling technologies.
We believe in the fundamental advantage of a diverse workplace and are committed to creating a fairer, more diverse healthcare investor and entrepreneurial community. Our commitment begins at APVC through the diversity of our investment team, and we extend this accountability to the companies we invest in.
Who we back
Who we are
Watch the APVC team speak at the 2020 Medtech Strategists Virtual Summit about bioelectronic medicine, investments, trends, and their commitment to diversity & inclusion.
Listen to APVC partner Juan-Pablo Mas speak with Tom Salemi of the Device Talks Weekly podcost about the potential of ultrasound in bioelectronic medicine
SetPoint Medical Raises $64M in Preferred Stock Financing to Support Pivotal Trial for its Novel Bioelectronic Platform